Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Although recent advances in chemotherapy have led to improved quality of life(QOL)and prolonged survival in patients with advanced cancer, treatment is often discontinued because of adverse events associated with chemotherapy, regardless of its efficacy.Nevertheless, chemotherapy has been validated in the United States and United Kingdom and is used worldwide. In Japan, few reports have been published regarding the use of assessment tools including the Multinational Association of Supportive Care in Cancer(MASCC)Antiemesis Tool(MAT)for the evaluation of chemotherapy-induced nausea and vomiting(CINV).We prospectively investigated the utility of the MAT and digestive symptom diary(DSD).In total, 68 patients who underwent highly and moderately emetogenic chemotherapy were included in the efficacy analyses.The improvement in the control of CINV during the delayed phase was significantly different between the DSD and MAT groups(p= 0.0148).The results obtained using the MAT warrant further validation.Meanwhile, the DSD may be used as an information tool by medical staff and patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in gastric cancer patients receiving adjuvant oxaliplatin and capecitabine after gastrectomy: a retrospective pilot study.
Korean J Clin Oncol
August 2025
Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with oxaliplatin-based chemotherapy in gastric cancer patients. Recent studies suggest that high-dose intravenous selenium may exert neuroprotective effects in patients receiving platinum-based chemotherapy.
Methods: This pilot study analyzed patients with stage III gastric adenocarcinoma who underwent gastrectomy between January and December 2024.
Development of 3D printed dexamethasone chewable tablets for prophylaxis of chemotherapy-induced nausea and vomiting in children.
Int J Pharm X
December 2025
University Medical Center Hamburg-Eppendorf, Hospital Pharmacy, Hamburg, Germany.
Dexamethasone (Dexa) is widely used for the prophylaxis of chemotherapy-induced nausea and vomiting. In pediatric patients, individual dosing often requires the manipulation of commercial tablets, leading to dose inaccuracies, higher treatment complexity and poor acceptance due to Dexa's intensely bitter taste. This study aimed to develop 3D-printed chewable Dexa tablets with effective taste masking for pediatric oncology.
View Article and Find Full Text PDFA Case of Possible Infusion-Related Reactions Caused by Palonosetron.
Case Rep Oncol
February 2025
Department of Second Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Introduction: An infusion-related reaction (IRR) is an adverse event that typically occurs when cytotoxic drugs or monoclonal antibodies are administered. Palonosetron, a 5-hydroxytryptamine 3 receptor antagonist, is commonly used to prevent chemotherapy-induced nausea and vomiting. IRRs due to palonosetron are very rare, with only two reports of anaphylactic shock due to palonosetron to date.
View Article and Find Full Text PDFDose-dependent Efficacy of Olanzapine for Chemotherapy-induced Nausea and Vomiting: A Systematic Review and Meta-analysis.
Anticancer Res
September 2025
Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan
Background/aim: This study aimed to investigate the efficacy of olanzapine, an antiemetic agent used to prevent chemotherapy-induced nausea and vomiting (CINV), at 5 and 10 mg/day, by chemotherapy emetogenic risk, and to evaluate the efficacy of low dose olanzapine at 2.5 mg/day.
Materials And Methods: PubMed and Web of Science were searched to identify studies evaluating the efficacy of olanzapine in CINV prevention from database inception up to August 31, 2023.
Palonosetron plus megestrol acetate versus palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: a randomized, multicenter, crossover trial.
J Pain Symptom Manage
August 2025
Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu 610041, Sichuan, China. Electronic address:
Backgrounds: Evidence shows that megestrol acetate (MA) is a potential antiemetic for preventing chemotherapy-induced nausea and vomiting (CINV). No persuasive clinical trials have been performed to validate the efficacy and safety of MA. Here we designed a randomized controlled trial to assess the efficacy of palonosetron plus megestrol acetate versus palonosetron plus dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy (MEC) regimens.
View Article and Find Full Text PDF